BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1912556)

  • 1. A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs.
    Makris M; Preston FE; Triger DR; Underwood JC; Westlake L; Adelman MI
    Blood; 1991 Oct; 78(7):1672-7. PubMed ID: 1912556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alfa for chronic hepatitis C in haemophiliacs.
    Makris M; Preston FE; Triger DR; Underwood JC; Westlake L; Adelman MI
    Gut; 1993; 34(2 Suppl):S121-3. PubMed ID: 8314476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon treatment for chronic hepatitis C infection in hemophiliacs--influence of virus load, genotype, and liver pathology on response.
    Hanley JP; Jarvis LM; Andrew J; Dennis R; Hayes PC; Piris J; Lee R; Simmonds P; Ludlam CA
    Blood; 1996 Mar; 87(5):1704-9. PubMed ID: 8634415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis.
    Bresci G; Del Corso L; Romanelli AM; Giuliano G; Pentimone F
    J Am Geriatr Soc; 1993 Aug; 41(8):857-62. PubMed ID: 7688007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course.
    Reichard O; Glaumann H; Norkrans G; Wejstål R; Fryden A; Schvarcz R; Weiland O
    Liver; 1994 Aug; 14(4):169-74. PubMed ID: 7526108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha-Interferon treatment of chronic hepatitis C in young patients with homozygous beta-thalassemia.
    Di Marco V; Lo Iacono O; Capra M; Grutta S; Ciaccio C; Gerardi C; Maggio A; Renda D; Almasio P; Pisa R
    Haematologica; 1992; 77(6):502-6. PubMed ID: 1289187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers.
    Rumi MG; Santagostino E; Morfini M; Gringeri A; Tagariello G; Chistolini A; Pontisso P; Tagger A; Colombo M; Mannucci PM
    Blood; 1997 May; 89(10):3529-33. PubMed ID: 9160657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C].
    Fernández I; Castellano G; Canga F; Colina F; García H; Fuertes A; Casis B; Martín A; Solís JA
    Gastroenterol Hepatol; 1995 Feb; 18(2):66-72. PubMed ID: 7621277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment.
    Weltman MD; Brotodihardjo A; Crewe EB; Farrell GC; Bilous M; Grierson JM; Liddle C
    J Viral Hepat; 1995; 2(1):39-45. PubMed ID: 7493293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C.
    Maeda T; Onishi S; Miura T; Iwamura S; Tomita A; Saibara T; Yamamoto Y
    Dig Dis Sci; 1995 Jun; 40(6):1226-30. PubMed ID: 7781437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection.
    Puoti M; Rossi S; Forleo MA; Zaltron S; Spinetti A; Putzolu V; Rodella A; Carosi G
    J Hepatol; 1998 Jul; 29(1):45-52. PubMed ID: 9696491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can the response to interferon treatment be predicted in patients with chronic active hepatitis C?
    Lin R; Schoeman MN; Craig PI; Bilous M; Grierson J; McDonald JA; Batey RG; Farrell GC
    Aust N Z J Med; 1991 Jun; 21(3):387-92. PubMed ID: 1953524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.
    Douglas DD; Rakela J; Lin HJ; Hollinger FB; Taswell HF; Czaja AJ; Gross JB; Anderson ML; Parent K; Fleming CR
    Dig Dis Sci; 1993 Apr; 38(4):601-7. PubMed ID: 8384978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A,non-B viral hepatitis. A randomized controlled trial.
    David E; Pucci A; Palladin D; Saracco G; Garello E; Pintus C; Rocca G; Chiandussi L; Solinas A; Mollo F
    Am J Clin Pathol; 1992 Oct; 98(4):397-401. PubMed ID: 1415021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan.
    Yoshikawa M; Fukui H; Kojima H; Yoshiji H; Sakamoto T; Imazu H; Nakanani T; Matsumura Y; Kuriyama S; Yamao J
    J Gastroenterol; 1995 Jun; 30(3):367-71. PubMed ID: 7647904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment.
    Orito E; Mizokami M; Suzuki K; Ohba KI; Ohno T; Mizuno M; Iijima Y; Saito H; Nemoto A; Nukuta N
    J Gastroenterol Hepatol; 1997 Jan; 12(1):58-61. PubMed ID: 9076625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of alpha-interferon for treatment of chronic hepatitis C in terms of histological changes with aminotransferase normalization and hepatitis C virus RNA seroconversion.
    Hosoda K; Yokosuka O; Kato N; Ito Y; Ohto M; Omata M
    Gastroenterol Jpn; 1993 May; 28 Suppl 5():115-7. PubMed ID: 8395437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B.
    Fattovich G; Brollo L; Boscaro S; Pontisso P; Giustina G; Criscuolo D; Maladorno D; Alberti A; Realdi G; Ruol A
    J Hepatol; 1989 Nov; 9(3):331-7. PubMed ID: 2691568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.